Core Viewpoint - The company expects a net profit attributable to shareholders of 15 million to 16 million yuan for the full year of 2025, driven by growth in the OTC hearing aid market and successful integration of acquired technology [1] Group 1: Performance Forecast - The company anticipates a year-on-year increase in net profit attributable to shareholders for 2025, primarily due to sustained demand in the U.S. OTC market and enhanced operational strategies [1] - The company has strengthened partnerships with key brand clients, leading to increased orders and revenue from brand partners [1] - The company has accelerated the development of its own brand channels, resulting in significant revenue growth from proprietary products [1] Group 2: Recent Financial Results - For the first three quarters of 2025, the company reported a main operating revenue of 196 million yuan, an increase of 82.44% year-on-year [2] - The net profit attributable to shareholders for the same period reached approximately 17.63 million yuan, reflecting a year-on-year increase of 565.54% [2] - The third quarter alone saw a main operating revenue of 82.22 million yuan, up 87.17% year-on-year, with a net profit of approximately 991.96 thousand yuan, marking a staggering increase of 1162.04% [2]
锦好医疗：预计2025年全年归属净利润盈利1500万元至1600万元